pERC

pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights   September 2020 Highlights: 1 product completed CADTH review 0 products initiated pCPA negotiations 2 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation   Files Under pCPA Consideration: CADTH issued 1 new recommendation in September (25 files as of September 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Zejula (niraparib) Ovarian…

pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights   August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Soliris (eculizumab) Neuromyelitis…

pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights   July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start…

pan-Canadian Pharmaceutical Alliance (pCPA): June 2020 Trends and Insights   June Highlights: 4 products completed CADTH review 7 products initiated pCPA negotiations 4 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 4 new recommendations in June (23 files as of June 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Cuvposa (glycopyrrolate) Chronic severe…

pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights   May Highlights: 8 products completed CADTH review 5 products initiated pCPA negotiations 0 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation.  No negotiations were completed or closed for the first…

pan-Canadian Pharmaceutical Alliance (pCPA): April 2020 Trends and Insights   April Highlights: 6 products completed CADTH review 4 products initiated pCPA negotiations 11 negotiations were completed with an LOI 2 negotiations were closed without an LOI 2 files were closed without negotiation In keeping with pCPA’s communication to industry associations, early trends into their management of files during the challenges associated with COVID indicate that initial priority has been on…

CADTH released its Pharmaceutical Reviews Update — Issue 15 on April 29, 2020.  Please find below MORSE Consulting’s summary of this update. Topic MORSE Note 1. COVID-19 Update CADTH will continue to deliver on core activities, including the completion of ongoing drug reviews and initiation of new reviews in accordance with target timelines, and progress reports will continue to be posted on the CADTH website. Pre-submission and expert committee meetings…

pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks. Highlights of the pCPA activity in March are: 5 products completed CADTH review, for a total of 16 files under consideration; 2 products initiated pCPA negotiations, for a total of 29…

pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights   Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations.  Highlights…

pan-Canadian Pharmaceutical Alliance (pCPA): January 2020 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the January 31, 2020 status of brand negotiations. Highlights since the last update include: ● 2 products completed CADTH review, for a total of 9 files under consideration; ● 4 products initiated pCPA negotiations, for a total of 34 active negotiations; ● 2 negotiations completed for a total of 297 completed negotiations; ●…

pan-Canadian Pharmaceutical Alliance (pCPA): December 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the December 31, 2019 status of brand negotiations.  Highlights since the last update include: 3 products completed CADTH review, for a total of 10 files under consideration; 0 products initiated pCPA negotiations, for a total of 32 active negotiations; 1 negotiation completed for a total of 295 completed negotiations; 1 negotiation closed, for…

pan-Canadian Pharmaceutical Alliance (pCPA): November 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the November 30, 2019 status of brand negotiations.  Highlights since the last update include: 6 products completed CADTH review, for a total of 9 files under consideration; 4 products initiated pCPA negotiations, for a total of 34 active negotiations; 12 negotiations completed for a total of 294 completed negotiations; No negotiations closed, for…

Summary of CADTH Drug Portfolio Information Session   Date: Monday, November 25, 2019 Time: 1:30 pm to 4:00 pm On November 25, 2019, CADTH hosted two information sessions in Toronto, Ontario for their Medical Device and Drug Portfolios. These annual sessions are an opportunity for stakeholders to get the latest information about priority initiatives and process changes. The summary below is separated into the following sections: Welcome and Strategic Overview…

pan-Canadian Pharmaceutical Alliance (pCPA): October 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the October 31, 2019 status of brand negotiations.  Highlights since the last update include: 4 products completed CADTH review, for a total of 7 files under consideration; 2 products initiated pCPA negotiations, for a total of 42 active negotiations; 6 negotiations completed for a total of 282 completed negotiations; 2 negotiation closed, for…

pan-Canadian Pharmaceutical Alliance (pCPA): September 2019 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the September 30, 2019 status of brand negotiations.  Highlights since the last update include: 4 products completed CADTH review, for a total of 6 files under consideration; 8 products initiated pCPA negotiations, for a total of 48 active negotiations; 6 negotiations completed for a total of 276 completed negotiations; 1 negotiation closed, for…